Gottlieb will speak at two sessions during the AIHD Conference, which takes place May 10-11 in San Jose. Expect his focus to be on the state of AI in healthcare.
Researchers at Weill Cornell Medicine believe they have discovered the variant protein that causes taxane-resistant cancer cells to develop.
By using organoids, “we can show that for a particular patient subset, for a particular drug, we can do better than the current selection criteria,” stated Else Driehuis, PhD.
The approach combined deep molecular profiling with comprehensive drug sensitivity testing for patients where standard therapy alternatives had been exhausted.
A recently FDA-recognized somatic cancer database organizes tumor genomic profiling and cancer drugs into levels of clinical evidence that can be used by hospital and oncology leaders.
Comprehensive assessment of young adult tumors across multiple cancer types reveals age-related cancer genetics that are important to treatment decisions.
UT Southwestern Medical Center research has discovered imaging biomarkers that can predict what response patients will have to antidepressant medications.
Personalized treatments for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (IDLs) step closer to reality as new study techniques and improved funding advance research.
Precision Medicine Research for Pulmonary Fibrosis May Bring New Treatments Closer Read More »
Renewed interest in abandoned drugs for specific subsegments of certain healthcare populations could lead to new personalized treatments for cancer and other chronic diseases.
Researchers have found that cancer cells have different states in which different sets of genes are expressed, influencing what drugs will be effective for those cells given that specific point in time.
